PharVision Advisers’s LifeMD LFMD Stock Holding History

PharVision Advisers’s Portfolio LFMD Stock Details LFMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-43,002	Closed	-$292K	–	865
2025 Q3	$292K	Buy	+43,002	New	+$355K	0.16%	237

Other funds holding LFMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

WCA

Whetstone Capital Advisors Shawnee Mission, Kansas $288M AUM 44.06% 1-Year Est. Return

PGCM

Prescott Group Capital Management Tulsa, Oklahoma $1B AUM 51.95% 1-Year Est. Return

PharVision Advisers's LFMD Position: Q4 2025 in Review

PharVision Advisers sold out of LifeMD (LFMD) in Q4 2025, closing a stake of 43,002 shares — an estimated $292K sold.

PharVision Advisers first reported a position in LFMD in Q3 2025 and held it in 1 quarter. The position peaked at $292K in Q3 2025. 104 funds tracked by Wall St. Rank hold LFMD as of Q4 2025.

PharVision Advisers reported no remaining LifeMD position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 43,002 LifeMD shares in Q4 2025, an estimated $292K.
PharVision Advisers first reported a position in LifeMD in Q3 2025 and held it in 1 quarter.
PharVision Advisers's LifeMD position peaked at $292K in Q3 2025.
104 funds tracked by Wall St. Rank held LifeMD as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.